Modernizing ClinicalTrials.gov will empower patients, oncologists, and others to better understand what trials are available, where they are available, and their up-to-date eligibility criteria, using standardized search categories to make them more easily discoverable.
The current lack of public trust in AI risks inhibiting innovation and adoption of AI systems, meaning new methods will not be discovered and new benefits won’t be felt. A failure to uphold high standards in the technology we deploy will also place our nation at a strategic disadvantage compared to our competitors.
We need a new agency that specializes in uncovering funding opportunities that were overlooked elsewhere. Judging from the history of scientific breakthroughs, the benefits could be quite substantial.
A shift toward more circular, transparent systems would not only reduce waste and increase efficiency, but also unlock new business models, strengthen supply chain resilience, and give consumers better, more reliable information about the products they choose.
AI safety is a rapidly evolving field that draws attention from a diverse range of policymakers across the political spectrum, including those in Congress, federal agencies, and state and local governments.
From using AI to optimize power grids to accelerating clean energy R&D, AI holds huge potential, while also introducing new challenges related to climate, equity, infrastructure, security, and sustainability.
What steps should the U.S. take to address China’s growing global share of legacy chip manufacturing?
As artificial intelligence evolves, so does the urgency for legislation to manage both the risks and opportunities associated with it.
We engage with the public, academia, and the private sector to foster a broader understanding of AI and emerging technology policy issues.
We’re scoping ambitious ideas to help ARPA-I begin executing projects that improve transportation across the country.
The U.S. bioeconomy is growing rapidly, innovation is needed to sustain and maintain this growth. Shaping policy to consider workforce development, advanced agriculture, bioindustrial and biotech sectors will be imperative to keep the needle moving forward.
We aim to catalyze a more nimble science funding ecosystem, capable of keeping up with and facilitating new innovations to improve the lives of people around the world.
